BioCryst Pharmaceuticals, Inc. (BCRX) Balance Sheet
As of 2026-06-30 (10-Q), BioCryst Pharmaceuticals, Inc. (BCRX) reported total assets of $557.9M, total liabilities of $1.0B and shareholders' equity of -$454.3M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $155.0M. Long-term debt: $395.4M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
BCRXBioCryst Pharmaceuticals, Inc.Follow BCRX — free
—
Price chart with a free account
- Market cap
- 2.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 16.4 | 20.9 | 21.2 | 54.5 | 28.9 | 22.1 | 50.3 | 26.7 | 114.2 | 272.1 | 504.4 | 304.8 | 110.6 | 104.7 | 89.7 | 155.0 | |
| Short-term investments | 25.3 | 14.7 | 16.9 | 18.2 | 22.7 | 32.5 | 64.1 | 77.7 | 22.1 | 28.2 | 3.2 | 119.5 | 278.3 | 216.1 | 185.0 | 197.6 | |
| Receivables | 5.8 | 4.6 | 2.1 | 3.8 | 6.2 | 8.8 | 6.1 | 4.3 | 22.1 | 8.2 | 2.0 | 50.6 | 57.0 | 79.1 | 106.8 | 110.8 | |
| Inventory | 0.3 | 4.0 | 4.0 | 0.7 | 1.6 | 0.5 | — | 1.6 | 0.0 | 7.0 | 15.8 | 27.5 | 28.7 | 8.1 | 5.4 | 6.1 | |
| Current assets | 52.9 | 42.0 | 42.1 | 89.3 | 63.8 | 67.0 | 125.4 | 114.4 | 164.3 | 323.8 | 566.1 | 516.5 | 496.0 | 422.0 | 404.3 | 484.7 | |
| Total assets | 82.2 | 57.4 | 48.9 | 136.9 | 122.4 | 89.8 | 178.3 | 146.8 | 175.3 | 334.7 | 588.2 | 550.0 | 517.0 | 490.4 | 514.2 | 557.9 | |
| Current liabilities | 26.3 | 17.2 | 15.3 | 57.3 | 62.3 | 54.4 | 74.8 | 69.5 | 92.3 | 105.7 | 103.7 | 105.5 | 150.0 | 160.4 | 196.1 | 208.8 | |
| Long-term debt | 30.0 | 30.0 | 30.0 | 30.0 | — | 23.0 | 23.0 | 30.0 | 0.0 | 119.7 | 136.1 | 231.6 | 303.2 | 314.9 | 0.0 | 395.4 | |
| Total liabilities | — | — | — | — | — | — | — | — | — | — | — | — | 972.5 | 966.4 | 633.3 | 1,012.1 | |
| Shareholders' equity | 14.8 | -0.5 | -1.1 | 75.6 | 47.7 | 1.6 | 83.8 | 49.2 | 38.3 | -19.3 | -107.0 | -294.6 | -455.5 | -475.9 | -119.2 | -454.3 |
USD millions · SEC XBRL
BioCryst Pharmaceuticals, Inc. — questions
- How much cash does BioCryst Pharmaceuticals, Inc. have?
- $155.0M in cash and cash equivalents as of 2026-06-30.
- How much debt does BioCryst Pharmaceuticals, Inc. have?
- $395.4M of long-term debt as of 2026-06-30.
- What are BioCryst Pharmaceuticals, Inc.'s total assets?
- $557.9M as of 2026-06-30.
- What is BioCryst Pharmaceuticals, Inc.'s shareholders' equity?
- -$454.3M as of 2026-06-30.
Every figure on this page comes from BioCryst Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.